Pharma–biotech partnership spotlighting AI-driven approaches to accelerate early-stage drug discovery and candidate optimization for multiple therapeutic areas.
Key Takeaways
- Insilico will receive about $60 million in upfront and near-term payments
- Takeda gains exclusive worldwide rights to develop and commercialize selected candidates
- Teams will use an end-to-end Pharma.AI generative platform to identify optimized drug candidates